UMI

Universal Media Inc. Promotes Kyle Cook to President/Chief Strategy Officer

Retrieved on: 
Friday, May 3, 2024
University, Courage, University of Pennsylvania, UMI, Division 1, EVP, Partnership, Universal Sports, Media strategy, York College, Acquisition, Marketing, MBA, Knowledge, Management

MECHANICSBURG, Pa., May 3, 2024 /PRNewswire/ -- Anne Carnathan, President & CEO of Universal Media, Inc. (UMI) and Universal Sports & Entertainment (USE), is proud to announce the promotion of Kyle Cook to President/Chief Strategy Officer effective May 1, 2024.

Key Points: 
  • MECHANICSBURG, Pa., May 3, 2024 /PRNewswire/ -- Anne Carnathan, President & CEO of Universal Media, Inc. (UMI) and Universal Sports & Entertainment (USE), is proud to announce the promotion of Kyle Cook to President/Chief Strategy Officer effective May 1, 2024.
  • Formerly EVP of Media Strategy, Cook first joined the UMI team in 2011 as Sales Coordinator.
  • In his new role, Cook will lead the diversification of innovative media and data offerings, while overseeing agency alignment and supporting the professional growth of all employees.
  • "We look forward to our continued partnership with UMI and Kyle Cook as he shifts into his new role as president.

QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024

Retrieved on: 
Wednesday, April 3, 2024
EGFR, Gene, Nested polymerase chain reaction, Professor, Cancer Institute, Circulating free DNA, Neoplasm, TCR, Research institute, QGEN, Research, PCR, Central business district, NGS, DNA, BRAF, Diagnosis, WIA, Cancer, Immune system, Liquid biopsy, UMI, Mutation, Genetics, Human genetics, Senior, AACR, Medical school, QIAGEN, Poster, Environment, IVD, Urine

Two Exhibitor Spotlight Theater sessions and several poster presentations will highlight additional advances from QIAGEN in this field.

Key Points: 
  • Two Exhibitor Spotlight Theater sessions and several poster presentations will highlight additional advances from QIAGEN in this field.
  • EGFR and BRAF are genes essential for normal cell growth and function, but mutations in these genes can result in cancer development.
  • To advance research on how the immune system interacts with cancer, QIAGEN has introduced the QIAseq Targeted RNA-seq Panel for T-cell receptors.
  • Learn more about QIAGEN’s offering at the AACR Annual Meeting 2024, (booth #922 in the San Diego Convention Center) and poster presentations highlighting new solutions in digital PCR, NGS and preanalytical workflows at https://www.qiagen.com/applications/cancer-research/aacr-2024-annual-mee... .

Universal Media Inc. Celebrates Growth of Universal Sports & Entertainment Division to Expand Experiential Marketing and Deepen Community Relationships

Retrieved on: 
Friday, January 5, 2024
Marketing, LAFC, Mickley, Philadelphia Eagles, Cleveland Cavaliers, Cleveland Guardians, Credit union, NIL, Heart, Live Nation Entertainment, Sport, Name, Penn State Nittany Lions, UMI, Philadelphia Flyers, Organization, IHeartMedia

UMI President and CEO Anne Carnathan appointed Nick Mickley as VP Integrated Media and Marketing Partnerships to lead the new division.

Key Points: 
  • UMI President and CEO Anne Carnathan appointed Nick Mickley as VP Integrated Media and Marketing Partnerships to lead the new division.
  • A media veteran who spent the past 17 years as an iHeart Media executive, Mickley is driven by a measurable impact on audience and consumer engagement.
  • "Sports and entertainment marketing must reach beyond placing signage in stadiums or names on arenas.
  • For more information about Universal Sports & Entertainment, or to schedule a sponsorship package review, contact Nick Mickley , VP, Integrated Media & Marketing Partnerships.

Cellecta, Inc. Launches DriverMap™ Adaptive Immune Receptor (AIR) Mouse RNA TCR and BCR Kits for Sensitive Immune Repertoire Profiling

Retrieved on: 
Thursday, November 16, 2023
TCR, B cell, Immune system, AIR, Mouse, Disease, Artifact, PCR, Library, BCR, NGS, CDR3, Complementarity, RNA, UMI, Vaccine

MOUNTAIN VIEW, Calif., Nov. 16, 2023 /PRNewswire/ -- Cellecta, Inc. today announced the launch of the DriverMap™ Adaptive Immune Receptor (AIR) Mouse RNA TCR and BCR kits. These new Mouse AIR assays supplement the line of multiplex-PCR, NGS-based T- and B-cell Receptor assays and, like Cellecta's current kits targeting human T- and B-cells, enable profiling of all seven T-cell receptor (TCR) and B-cell receptor (BCR) chains in a single reaction without need of specialized equipment.

Key Points: 
  • MOUNTAIN VIEW, Calif., Nov. 16, 2023 /PRNewswire/ -- Cellecta, Inc. today announced the launch of the DriverMap™ Adaptive Immune Receptor (AIR) Mouse RNA TCR and BCR kits.
  • These new Mouse AIR assays supplement the line of multiplex-PCR, NGS-based T- and B-cell Receptor assays and, like Cellecta's current kits targeting human T- and B-cells, enable profiling of all seven T-cell receptor (TCR) and B-cell receptor (BCR) chains in a single reaction without need of specialized equipment.
  • The kits include all PCR reagents and primers required to generate next-generation sequencing (NGS)-ready libraries.
  • The DriverMap AIR TCR and BCR Repertoire Profiling portfolio now includes:

Pillar Biosciences to Present New Scientific Data at Association for Molecular Pathology Annual Meeting

Retrieved on: 
Wednesday, November 8, 2023
Pillar, Laboratory, NSCLC, Liquid biopsy, AMP, IVD, Bandwidth (signal processing), Microsatellite instability, Automation, MSI, Neoplasm, Research, Microdissection, AM, Beckman Coulter, Detection, Chemistry, Test management, UMI, RUO, Methylation, NGS, Targeted molecular therapy for neuroblastoma, CRC, Health care, Partnership, HRD, Urinary cell-free DNA, Column, Pension fund, Medical imaging, Instrumentation, Multiplexing

NATICK, Mass., Nov. 8, 2023 /PRNewswire/ -- Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced the company and scientific collaborators will collectively present eleven studies and two corporate workshops at the 2023 Association for Molecular Pathology (AMP) Annual Meeting from November 14 -18, 2023 in Salt Lake City, UT (Booth #619).

Key Points: 
  • NATICK, Mass., Nov. 8, 2023 /PRNewswire/ -- Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced the company and scientific collaborators will collectively present eleven studies and two corporate workshops at the 2023 Association for Molecular Pathology (AMP) Annual Meeting from November 14 -18, 2023 in Salt Lake City, UT (Booth #619).
  • "Pillar Biosciences is committed to developing the data necessary to support the quality, accuracy and value of our leading IVD & RUO kitted products which can be used locally by laboratories to perform NGS sequencing," said Randy Pritchard, CEO of Pillar Biosciences, Inc. "We are proud to present these data in partnership with our collaborators at this year's AMP Annual Meeting as we continue to enable more laboratories globally with NGS assays that can be performed in a low-cost, high-multiplexed manner, thus enabling actionable, accessible NGS profiling results."
  • The scientific data presented at AMP will focus on Pillar Biosciences oncoReveal™ Research-Use-Only (RUO) kitted NGS products for liquid biopsy (LBx), HRD, methylation, solid tumor and automation.
  • Localized NGS-based Methylation Testing to Help Inform BioPharma Clinical Trials and Improve Patient Care in Oncology (Room 251F: 8:00-8:50 AM MDT)
    Highly Accurate and Automated NGS assays for Efficient Localized LBx and TBx Clinical Testing in Oncology (Room 251F: 9:00-9:51 AM MDT)
    Comparative Laboratory Performance Evaluation of Pillar Biosciences, ArcherDx, and ThermoFisher Sequencing Chemistries for The Targeted Characterization of CRC & NSCLC Samples (Poster Number: ST120)
    Robust Low Frequency Somatic Variant Detection in cfDNA Using a SLIMamp® Based Liquid Biopsy Assay (Poster Number: ST035)
    Detection of Microsatellite Instability (MSI) Using oncoReveal Core LBx, a Multiplexed, Single Tube, Liquid Biopsy Assay (Poster Number: ST107)
    Automation of The Pillar Biosciences oncoReveal Solid Tumor 22 gene panel (ORST22) on the Biomek NGeniuS Next Generation Library Prep System (Poster Number: ST029)
    QCPRECISE!™: An Automated Spatially Targeted Microdissection Platform Driven by AI Guided Digital Pathology Improves Extracted Solid Tumor DNA Purity Relative to Conventional Macrodissection (Poster Number: TT007)
    To UMI or Not to UMI: Obtaining Robust Low-Frequency Variant Identification for Liquid Biopsy with a SLIMamp-Based NGS Chemistry Without Molecular Barcoding (Poster Number: ST145)
    Robust Bioinformatic Method for Estimating Tumor Content in cfDNA Using Denoised Target Sequencing (Poster Number: I031)
    Pillar Biosciences oncoReveal methylQuant Panels: Accurate and Easy-to-Use Methylation NGS Assays Leveraging SLIMamp Technology (Poster Number: ST031)
    oncoReveal Fusion LBx: Single-Tube Multiplexed PCR-Based NGS assay for Detection of Multiple Gene Fusions from Cell Free RNA (Poster Number: ST041)
    Robust Detection of Copy Number Amplifications Using Pillar's oncoReveal™ Core LBx Panel with Low Input from Liquid Biopsy Samples (Poster Number: I011)
    Poster and abstract summaries of this research will be available onsite at Pillar Biosciences' booth #619.

BioBam Launches OmicsBox 3.1: Revolutionizing Omics Data Analysis

Retrieved on: 
Tuesday, October 3, 2023
Research, Technology, Genetics, Professional Services, Software, Biotechnology, Data Analytics, Health, Science, Other Science, Abraxis BioScience, Single-cell analysis, B cell, Multimedia, GWAS, Genomics, RNA-Seq, UMI, Genetic variation, ONT, Mobile phone, BioBam Bioinformatics

BioBam, the leading bioinformatics software company, is pleased to announce OmicsBox 3.1, its latest version packed with innovative features designed to empower researchers, scientists, and bioinformaticians in their pursuit of advanced omics data analysis and interpretation.

Key Points: 
  • BioBam, the leading bioinformatics software company, is pleased to announce OmicsBox 3.1, its latest version packed with innovative features designed to empower researchers, scientists, and bioinformaticians in their pursuit of advanced omics data analysis and interpretation.
  • View the full release here: https://www.businesswire.com/news/home/20231003214238/en/
    OmicsBox has consistently led the way by providing comprehensive genomics, transcriptomics, and metagenomics data analysis tools.
  • This release represents a significant step forward, introducing new Single-Cell analysis capabilities, strengthening Long-Read transcriptome analysis, and enhancing Genetic Variation analysis.
  • In the Long-Read Transcriptome data analysis, OmicsBox 3.1 introduces a new read aligner, complementing well-established tools like Flair, IsoSeq, and Sqanti.

Bridg Launches Rippl Data and Media Network

Retrieved on: 
Thursday, August 17, 2023
Office Bridge, NRS, ROI, National Retail Solutions, Investment, Schnucks, SKU, UMI, Retail, Gulf Bridge International, Ripple Labs

ATLANTA, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Bridg, a division of Cardlytics, Inc. (NASDAQ: CDLX), today announced the launch of Rippl, a data and media network, in order to unlock collaborative and profitable retail media partnerships for regional retailers and advertisers.

Key Points: 
  • ATLANTA, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Bridg, a division of Cardlytics, Inc. (NASDAQ: CDLX), today announced the launch of Rippl, a data and media network, in order to unlock collaborative and profitable retail media partnerships for regional retailers and advertisers.
  • Rippl provides a single point of access to anonymized shopper profiles enriched with SKU-level data across retailers.
  • Increased campaign investment, new monetization opportunities in both data and media, and refined synergies in partner collaboration encompassing trade and media spend, product innovation, and messaging are all part of Rippl’s value proposition.
  • Our retailer partners will benefit from advertiser investments that drive increased visits and spend.”
    Access to the Rippl data and media network is available today.

AFROPUNK BROOKLYN 2023 Announces Lineup, With Headliners Jazmine Sullivan and Flying Lotus

Retrieved on: 
Thursday, June 22, 2023
Music, African American, Consumer, Events, Concerts, Entertainment, Heart, Food, Lucky Daye, Exhibition, Life, Poetry, Culture, Tree, Calendar, Multimedia, Root, Doechii, Heaux Tales, UMI, The Beatnuts, Carnivalesque, Sudan Archives, Lotus, Nightclub, Black, DBN Gogo

Celebrating great music and vibrant culture in its home borough once again, AFROPUNK announces the lineup for AFROPUNK BROOKLYN 2023.

Key Points: 
  • Celebrating great music and vibrant culture in its home borough once again, AFROPUNK announces the lineup for AFROPUNK BROOKLYN 2023.
  • With additional performances from some of the most vital artists in music today, AFROPUNK returns to Brooklyn on August 26-27, 2023 at Greenpoint Terminal Market.
  • View the full release here: https://www.businesswire.com/news/home/20230622472564/en/
    In addition to this year’s masterful headliners, AFROPUNK BROOKLYN 2023 promises a lineup full of some of the hottest artists in music today.
  • For updates about AFROPUNK BROOKLYN 2023, please join our text community, sign-up for our newsletter and visit: https://afropunk.com/festival/brooklyn/
    View source version on businesswire.com: https://www.businesswire.com/news/home/20230622472564/en/

Fluent BioSciences Releases Comprehensive White Paper Highlighting Increased Performance Metrics with the Latest v4.0 PIPseq Single Cell RNA Sequencing Kits

Retrieved on: 
Thursday, May 4, 2023
SVP, Fluency, UMI, Fine chemical

WATERTOWN, Mass., May 2, 2023 /PRNewswire/ -- Fluent BioSciences, a leading life sciences company focused on revolutionizing single cell analysis through simple, cost effective and scalable solutions, has published a white paper highlighting the performance improvements of the recently announced v4.0 chemistry as compared to the previous v3.0 chemistry.

Key Points: 
  • WATERTOWN, Mass., May 2, 2023 /PRNewswire/ -- Fluent BioSciences, a leading life sciences company focused on revolutionizing single cell analysis through simple, cost effective and scalable solutions, has published a white paper highlighting the performance improvements of the recently announced v4.0 chemistry as compared to the previous v3.0 chemistry.
  • The v4.0 chemistry enables users to achieve higher capture rates, significantly higher sensitivity and improved sequencing efficiency.
  • The latest version is now available across the entire PIPseq portfolio of 3' Single Cell RNA Kits to address the demand for simple, cost-effective, and scalable solutions for single cell analysis.
  • "Our v4.0 chemistry for 3' single cell sequencing is just the beginning.

Cellecta, Inc. Launches DriverMap™ Adaptive Immune Receptor (AIR) Assay to Provide Greater Insights into Immune Repertoire Diversity by Profiling T-Cell and B-Cell Receptor Variability in Genomic DNA

Retrieved on: 
Wednesday, April 12, 2023
Antigen, DNA, DNA methylation, BCR, Off-target genome editing, RNA-Seq, RNA, Comprehensive, TCR, PBMC, AIR, Immune system, Medicine, UMI, PCR, Vaccine

MOUNTAIN VIEW, Calif., April 12, 2023 /PRNewswire/ -- Cellecta, Inc. today announced the launch of the DriverMap™ Adaptive Immune Receptor DNA (AIR-DNA) TCR and BCR kits which provide rapid, single-tube PCR-based assays to analyze the genomic diversity of receptors from T-cells or B-cells from a wide range of sample types, including whole blood, tissue biopsies, FFPE and more.

Key Points: 
  • The multiplex-PCR assays profile the variations of the four T-cell receptor (TCR) or three B-cell receptor (BCR) chains present in the genomic DNA of immune samples.
  • The assay results are obtained through next generation sequencing and provide important information on the abundance and diversity of T- or B-cell clonotypes in each sample.
  • "We are pleased to introduce the DriverMap AIR-DNA assays, which along with our AIR-RNA profiling assays provide researchers with more effective tools for immune receptor repertoire profiling.
  • In addition to offering the DriverMap AIR-DNA and AIR-RNA kits, Cellecta continues to provide the DriverMap AIR-DNA or AIR-RNA Profiling assays as a service.